The University of Liège wishes to use cookies or trackers to store and access your personal data, to perform audience measurement. Some cookies are necessary for the website to function. Cookie policy.
Statistics of Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM)
